Global PEGylated Proteins Market Report 2024: Revenue Data for 2021-2022, Estimates for 2023, Forecasts for 2024, and CAGR Projections through 2028 [Yahoo! Finance]
Amgen Inc. (AMGN)
Last amgen inc. earnings: 4/30 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.amgen.com
Company Research
Source: Yahoo! Finance
The global market for PEGylated proteins is expected to grow from $10.2 billion in 2023 and is projected to reach $15.9 billion by the end of 2028, at a compound annual growth rate (CAGR) of 9.4% during the forecast period of 2023 to 2028. This report highlights the current and future market potential of PEGylated proteins and provides a detailed analysis of the drivers, restraints, and opportunities in this market. The report also surveys the competitive environment for PEGylated proteins, including coverage of the pipeline activities adopted by players in this market, and it includes market projections for 2028. Also included are company profiles of key players featuring detailed information about each company's business segments, financials, product portfolios and recent developments. The report does not cover PEGylated vaccines. In this report, the global market for PEGylated proteins market is segmented into four regions: North America, Europe, Asia-Pacific and the Rest of
Show less
Read more
Impact Snapshot
Event Time:
AMGN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AMGN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AMGN alerts
High impacting Amgen Inc. news events
Weekly update
A roundup of the hottest topics
AMGN
News
- FDA Roundup: May 17, 2024 [Yahoo! Finance]Yahoo! Finance
- Amgen's (AMGN) Tarlatamab Receives FDA Approval for SCLC [Yahoo! Finance]Yahoo! Finance
- U.S. FDA approves Amgen drug for small cell lung cancer [Globe and Mail, The (Toronto, Canada)]Globe and Mail, The
- FDA APPROVES IMDELLTRA™ (TARLATAMAB-DLLE), THE FIRST AND ONLY T-CELL ENGAGER THERAPY FOR THE TREATMENT OF EXTENSIVE-STAGE SMALL CELL LUNG CANCERPR Newswire
- FDA Approves Amgen Drug for Persistently Deadly Form of Lung Cancer [The New York Times]The New York Times
AMGN
Earnings
- 5/2/24 - Beat
AMGN
Sec Filings
- 5/10/24 - Form DEFA14A
- 5/9/24 - Form 4
- 5/9/24 - Form 4
- AMGN's page on the SEC website